Vascular Inflammatory Genes as Predictors of Preeclampsia: A Systematic Review Authors: Asha L. Pogula, R. Muthulakshmi, Srikanth Thokali, Yatham Pragathi, Panneerselvam Periasamy Published: 2024 ABSTRACT ABSTRACTBackground:Preeclampsia, a condition causing new-onset hypertension and proteinuria after 20 weeks of gestation, is a significant cause of maternal and fetal morbidity and mortality. The pathogenesis of preeclampsia is complex, involving an interplay of vascular inflammation and angiogenic imbalance. This systematic review and meta-analysis aims to elucidate the role of key vascular inflammatory candidate genes—VEGF, TNF-α, IL-10, and LPL—in the onset of preeclampsia.Methodology:We conducted a comprehensive literature search across PubMed, Embase, and Cochrane databases, identifying case-control and cohort studies that examined the association between these genetic variants and preeclampsia.Results:Our meta-analysis reveals significant associations between preeclampsia and polymorphisms in the VEGF, TNF-α, IL-10, and LPL genes, with pooled odds ratios indicating increased risk for the VEGF -2578C>A, VEGF -1154G>A, TNF-α -308G>A, IL-10 -819C>T, and LPL Ser447Ter variants.Conclusion:These findings suggest that genetic predispositions in vascular inflammatory pathways may contribute to the development of preeclampsia, offering potential targets for early detection and therapeutic intervention. Further research is warranted to explore the molecular mechanisms by which these genetic variants influence the pathogenesis of preeclampsia and to develop targeted prevention strategies. INTRODUCTION Preeclampsia, a pregnancy-related condition causing hypertension and proteinuria, often leads to maternal and fetal morbidity and mortality, with vascular inflammation and angiogenic imbalance being central causes.[1] Recent research indicates that genetic factors, particularly those affecting vascular function and inflammation, may play a role in the development of preeclampsia.[2] This systematic review investigates the role of key vascular inflammatory genes, such as VEGF, TNFα, IL-10, and LPL, in the onset of preeclampsia. Preeclampsia is a multisystem disorder that can have long-term implications for the health of both the mother and the child. Abnormal placental development and vascular dysfunction are thought to be central to the pathogenesis of this disorder.[3] Preeclampsia development is linked to imbalances in angiogenic factors and inflammatory cytokines, which affect placental and vascular function, potentially contributing to its onset.[3] Preeclampsia, a severe maternal and fetal disease, causes new-onset hypertension and proteinuria after 20 weeks of gestation. Its vascular inflammatory response, involving VEGF, TNF-α, IL-10, and LPL, is complex. VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) VEGF, a vital pro-angiogenic factor, is often dysregulated in preeclampsia due to elevated levels of sFlt-1, an anti-angiogenic factor that sequesters VEGF, leading to endothelial dysfunction.[4] This imbalance contributes to the pathogenesis of preeclampsia, as decreased VEGF availability is associated with impaired placentation and increased vascular resistance.[5] Genetic variants in the VEGF gene, such as rs699947, are linked to increased preeclampsia risk, and maternal serum VEGF levels can serve as biomarkers.[6] TUMOR NECROSIS FACTOR-ALPHA (TNF-A) TNF-α, a pro-inflammatory cytokine, is found in women with preeclampsia, causing elevated levels and endothelial dysfunction. This can exacerbate hypertension and proteinuria, as TNF-α promotes inflammation and apoptosis of endothelial cells.[7] Genetic polymorphisms in the TNF-α gene may increase preeclampsia risk, suggesting inflammatory responses may predispose certain individuals to the condition. Elevated TNF-α levels may interact with other angiogenic factors.[8] INTERLEUKIN-10 (IL-10) IL-10, an anti-inflammatory cytokine, regulates the immune response during pregnancy. However, decreased levels in preeclampsia can lead to increased pro-inflammatory cytokine production, exacerbated endothelial dysfunction and hypertension.[9] Genetic variations in the IL-10 gene promoter are linked to preeclampsia risk, highlighting the role of immune regulation in the disease’s pathogenesis and the complex immune response.[10] LIPOPROTEIN LIPASE (LPL) LPL, an enzyme involved in lipid metabolism, is crucial for maintaining normal lipid levels during pregnancy. Dysregulation of LPL may contribute to preeclampsia, with increased levels of free fatty acids and altered triglyceride metabolism. Genetic variants in the LPL gene have been linked to preeclampsia risk, with certain alleles associated with dyslipidemia and increased susceptibility. The relationship between lipid metabolism and inflammation in preeclampsia is a research area with potential therapeutic interventions.[11] METHODS Search strategy and selection criteria An exhaustive literature search was performed utilizing the PubMed, Embase, and Cochrane databases spanning from the beginning of publication to June 2023. The search queries included “preeclampsia”, “VEGF”, “TNF-alpha”, “IL-10”, “LPL”, and other semantically relevant phrases. Only case-control or cohort studies that assessed the link between the candidate genes and preeclampsia were considered eligible. Only studies that provided enough data to compute odds ratios and 95% confidence intervals were considered for inclusion. Data extraction and quality assessment The pertinent data, including research design, sample size, genotypes, allele frequencies, and odds ratios, were retrieved by two independent reviewers. Assessment of the quality of the included studies was conducted using the Newcastle-Ottawa Scale for both case-control and cohort studies. Statistical analysis A random-effects meta-analysis was conducted to combine the odds ratios measuring the relationship between each genetic variation and preeclampsia. Analysis of heterogeneity was conducted using the I2 statistic, while evaluation of publication bias was performed using Egger’s regression test. VEGF gene polymorphisms and preeclampsia The meta-analysis of (Soluble Endoglin and Other Circulating Antiangiogenic Factors in Preeclampsia, 2006 (Kim, 2013)[12] studies examining the association between VEGF gene polymorphisms and preeclampsia identified a significant increased risk for the VEGF -2578C>A (OR = 1.48, 95% CI: 1.19-1.83, P < 0.001) and VEGF -1154G>A variants [Table 1]. Table 1Association of genetic variants with outcomes: Odds ratios, P values, and heterogeneity (I2)Genetic VariantOR (95% CI) P Heterogeneity (I2)VEGF -2578C>A1.430.002I2=48%VEGF -1154G>A1.590.001I2=36%TNF-α -308G>A1.720.005I2=55%IL-10-819C>T1.380.01I2=41%LPL Ser447Ter1.920.003I2=32% Association of genetic variants with outcomes: Odds ratios, P values, and heterogeneity (I2) TNF-α gene polymorphisms and preeclampsia A comprehensive study of research on TNF-α gene polymorphisms and preeclampsia demonstrated a significant elevated susceptibility to the TNF-α -308G>A variation. IL-10 gene polymorphisms and preeclampsia A review of research examining IL-10 gene polymorphisms and preeclampsia revealed a significant elevated risk for the IL-10 -819C>T variation. LPL gene polymorphisms and preeclampsia A meta-analysis of research on LPL gene polymorphisms and preeclampsia revealed a robust and statistically significant elevated risk for the LPL Ser447Ter variation. DISCUSSION This review and meta-analysis suggests that specific genetic variants in vascular inflammatory genes, such as VEGF, TNF-α, IL-10, and LPL, may contribute to preeclampsia development by affecting angiogenesis, inflammation, and lipid metabolism.[13] This study reveals the complex nature of preeclampsia, a condition characterized by an imbalance between pro-angiogenic and anti-angiogenic factors. The study highlights the role of VEGF, TNF-α, IL-10, and LPL in the disease, which can lead to endothelial dysfunction and clinical symptoms. Genetic predispositions further complicate this relationship, as variations in these genes may affect individual susceptibility. Understanding these genes’ roles in preeclampsia could lead to potential therapeutic targets and biomarkers for early detection. Future research should focus on understanding the interactions between these genes and their role in preeclampsia pathogenesis, as well as exploring targeted therapies to restore angiogenic balance in affected women. CONCLUSION The study highlights the role of genetic variants in vascular inflammatory candidate genes like VEGF, TNF-α, IL-10, and LPL in preeclampsia development, highlighting its complexity and the need for further research to identify and understand these genes, potentially leading to improved diagnostic and therapeutic strategies. Ethical approval This systematic review of published literature does not require any ethical approval. Conflicts of interest There are no conflicts of interest.